1. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay
- Author
-
S.K. Phua, Y.L. Liang, Tar Choon Aw, Helen M. L. Oh, C.S. Lau, and S.P. Hoo
- Subjects
0301 basic medicine ,Male ,Clinical Biochemistry ,Biochemistry ,law.invention ,Automation ,0302 clinical medicine ,law ,Limit of Detection ,Medicine ,Assay evaluation ,Polymerase chain reaction ,CDC, Centers for Disease Control and Prevention ,Reactivity index ,COVID-19, Coronavirus disease 2019 ,medicine.diagnostic_test ,General Medicine ,Hepatitis B ,Middle Aged ,030220 oncology & carcinogenesis ,Female ,SARS-CoV-2, Novel severe acute respiratory syndrome coronavirus 2 ,RCPA, Royal College of Pathologists of Australasia ,Adult ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,HCW, Healthcare worker ,Cross Reactions ,Article ,Antibodies ,03 medical and health sciences ,Betacoronavirus ,Predictive Value of Tests ,parasitic diseases ,RF, Rheumatoid factor ,Rheumatoid factor ,Humans ,CAP, College of American Pathologists ,Chemiluminescence ,Detection limit ,Biochemistry, medical ,business.industry ,SARS-CoV-2 ,ds-DNA, double-stranded DNA antibody ,fungi ,Biochemistry (medical) ,Assay sensitivity ,medicine.disease ,Virology ,FDA, Food and Drug Administration ,030104 developmental biology ,ANA, anti-nuclear antibody ,Immunoassay ,Immunoglobulin G ,Luminescent Measurements ,business - Abstract
Highlights • An extensive evaluation of the Abbott SARS-CoV-2 IgG assay. • The assay shows excellent sensitivity/specificity with little cross-reactivity. • Healthy volunteers and pre-pandemic samples had similar antibody cut-off indexes. • A lower, optimised limit for reactivity improves sensitivity in early disease., Introduction We describe our evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser. Methods We assessed assay precision, sensitivity, specificity, positive/negative predictive values (PPV/NPV), cross-reactivity (influenza/dengue/hepatitis B and C/rheumatoid factor/anti-nuclear/double-stranded DNA/syphilis) and sample throughput in samples from real-time polymerase chain reaction (RT-PCR) positive patients/healthcare workers (HCWs)/pre-pandemic samples. We compared the cut-off indexes (COIs) between all control samples (HCWs and pre-pandemic) to generate an optimised COI limit for reactivity. Results The assay specificity was 99.8% (n = 980) and sensitivity was 45.9–96.7% (n = 279). When tested ≥ 14 days post-positive RT-PCR (POS), the PPV/NPV was 96.4%/99.8%. The difference between the COIs of HCWs/pre-pandemic samples was small (0.01, p
- Published
- 2020